Related Experiment Video
Updated: Jul 17, 2026
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
A summary of the findings from the Post-CABG trial
B J Hoogwerf1, D B Hunninghake, G Knatterud
1Cleveland Clinic Foundation, University of Minnesota, Cleveland, USA.
Insights
Aggressive lipid-lowering therapy significantly reduced atherosclerosis progression in saphenous vein grafts after coronary artery bypass grafting (CABG). Low-dose warfarin did not alter graft disease progression but was associated with reduced clinical events during extended follow-up.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Pharmacology
Background:
- Saphenous vein grafts (SVGs) are prone to atherosclerosis after Coronary Artery Bypass Grafting (CABG).
- Lipid-lowering strategies and anticoagulation are potential interventions to mitigate SVG disease progression.
Purpose of the Study:
- To evaluate the impact of two distinct lipid-lowering strategies and low-dose warfarin versus placebo on atherosclerosis progression in SVGs post-CABG.
- To assess the effect of these interventions on composite clinical endpoints.
Main Methods:
- The Post-CABG trial employed a 2x2 factorial design.
- Quantitative angiography was used to compare baseline and follow-up angiograms (mean interval: 4.3 years) to assess atherosclerotic progression in SVGs.
- Composite clinical endpoints including death, myocardial infarction, stroke, PTCA, or repeat CABG were analyzed.
Main Results:
- An aggressive lipid-lowering strategy significantly reduced SVG disease progression compared to a moderate strategy.
- Low-dose warfarin did not significantly alter SVG atherosclerotic progression.
- The aggressive lipid strategy demonstrated benefits across multiple participant subgroups.
- Extended follow-up revealed reduced clinical events associated with the aggressive lipid strategy and low-dose warfarin.
Conclusions:
- Aggressive lipid lowering is effective in reducing atherosclerosis progression in SVGs after CABG.
- Low-dose warfarin may offer clinical benefits independent of its effect on SVG atherosclerosis.
- These findings support aggressive lipid management post-CABG to improve graft patency and clinical outcomes.
Abstract:
The Post-CABG trial was designed to assess the effects of 2 different lipid lowering strategies and low dose warfarin vs placebo (2 x 2 factorial) design on the progression of atherosclerosis in saphenous vein grafts. Atherosclerotic progression was determined by comparing baseline and follow-up angiograms (mean interval: 4.3 years) using quantitative angiography. Significant progression of disease in SVG's was reduced with the aggressive lipid lowering strategy compared to the moderate strategy; significant progression in SVG's was not altered by low dose warfarin. The beneficial effects on angiographic changes were demonstrated in multiple subgroups of participants in the trial. The composite clinical end point of death, MI, stroke, PTCA or repeat CABG was analyzed at the end of the trial and 3 years (extended follow-up) after closure of the angiographic trial. At the time of the extended follow-up the aggressive lipid strategy was associated with reduced clinical events; low dose warfarin was also associated with reduced clinical events.
More Related Videos
09:12Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
Published on: March 27, 2018
05:25Surgical Porcine Model of Chronic Myocardial Ischemia Treated by Exosome-laden Collagen Patch and Off-pump Coronary Artery Bypass Graft
Published on: September 15, 2023
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies